Mood struggles shadow type 2 diabetes in more than four in ten adults

Anxiety and depressive symptoms are highly common among people with type 2 diabetes yet often go undiagnosed. That matters beyond the distress itself: the authors note these conditions can impair adherence to treatment, contribute to chronic complications, reduce quality of life and, in severe cases, increase mortality. Individual studies have reported very different rates, partly because they used different questionnaires and different thresholds for what counts as a positive screen. This review set out to pool the available evidence into a single estimate and to explore why the numbers vary so much from study to study.

The researchers searched five databases, PubMed, Embase, PsycINFO, Scopus and Web of Science, from their inception to July 2026, screening 6,948 records under PRISMA 2020 guidance. They included studies of adults with type 2 diabetes that reported the prevalence of anxiety or depressive symptoms using validated screening instruments or diagnostic criteria. Two reviewers independently screened records, extracted the data and assessed each study's risk of bias. In the end, 34 studies involving 21,024 participants were included, each a one-time snapshot of a population, and separate pooled analyses were run for anxiety and for depression.

The pooled prevalence was 43.82% for anxiety symptoms and 41.83% for depressive symptoms, with wide ranges around both figures: 36.86 to 50.90 for anxiety and 33.83 to 50.06 for depression. Estimates varied substantially depending on which assessment instrument and cut-off point a study used. Several studies reported links with sex, glycaemic control and social support, but differences in definitions and methods meant these factors could not be pooled quantitatively. The authors stress that the extreme disagreement between studies limits how far the averages can be trusted as universal figures.

The result confirms a picture clinicians have long suspected: mood symptoms travel with type 2 diabetes far more often than they are diagnosed. It also complicates it, by showing that the headline number depends heavily on which questionnaire and threshold researchers pick, which is why past studies have disagreed so sharply. The open questions are practical ones: which instruments should become standard, which subgroups carry the highest burden, and how sex, glycaemic control and social support shape the risk. The authors are explicit that these are estimates of symptoms, not of clinically diagnosed anxiety or depressive disorders.

If you or someone close to you manages type 2 diabetes, this is a reason to treat persistent low mood or anxiety as a common companion of the condition rather than a personal failing. Because the figures come from screening questionnaires, a positive screen is a prompt for a proper conversation, not a diagnosis in itself. The wide variation between studies also means the true rate in any one clinic or country could sit well above or below the pooled averages. The broad message stands regardless: mood symptoms alongside type 2 diabetes are frequent, consequential and worth taking seriously.